|
PRTA | Prothena Corp Public Ltd Co |
|
|
PRTA | Prothena Corp Public Ltd Co |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 1.93 |
| Leverage | 12.95% |
| Market Cap | $ 451.8m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -150.9m |
| Margin | -260.35% |
Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases in the United States. The company is headquartered in Dublin, Ireland.